Findings

What do systematic reviews say?

50 questions · 54 findings · 1 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 5.6%GRADE not reported 1 · 1.9%Very low 0 · 0%Low 19 · 35.2%Moderate 23 · 42.6%High 8 · 14.8%

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

PAP · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 61 participants
Moderate

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Cardiac index · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

PVR · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

RAP · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension due to left‐heart disease

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i probably leads to lower improvement in WHO functional class compared with placebo (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.53 [0.32, 0.87]
3 studies · 285 participants
Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Six‐minute walk distance · people with pulmonary hypertension due to left‐heart disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 284 participants
Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension due to left‐heart disease

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i showed no clear difference in mortality compared with placebo (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.27 [0.28, 5.8]
3 studies · 286 participants
Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension due to left‐heart disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 52 participants
Low

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

PAP · people with pulmonary hypertension due to left‐heart disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Cardiac index · people with pulmonary hypertension due to left‐heart disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 96 participants
Moderate